PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

voriconazole Side Effects

The reactions most often reported to the FDA for voriconazole (also sold as Vfend), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

29,380
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of voriconazole come from 29,380 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 29,380 reports to the FDA Adverse Event Reporting System (FAERS) for voriconazole (Vfend): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

29,380

Reports Mentioning Death

8,672

29.5% of reports — not proof the medicine caused the death

Hospitalizations

11,781

40.1% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

DRUG INTERACTION
2,315
DEATH
1,460
PYREXIA
1,411
PNEUMONIA
1,321
CONDITION AGGRAVATED
1,093
BRONCHOPULMONARY ASPERGILLOSIS
1,028
FEBRILE NEUTROPENIA
888
ASPERGILLUS INFECTION
873
RESPIRATORY FAILURE
836
DIARRHOEA
759
NAUSEA
752
DYSPNOEA
725
NEUTROPENIA
706
SEPSIS
693
SEPTIC SHOCK
674
HALLUCINATION
671
MULTIPLE ORGAN DYSFUNCTION SYNDROME
648

Who Reports Side Effects

Gender Distribution

Female 10,218 (39%)
Male 15,918 (61%)
Unknown 144

Age Distribution

0-17 3,098 (13%)
18-44 4,502 (20%)
45-64 7,577 (33%)
65-74 5,136 (22%)
75+ 2,771 (12%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 8,672 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 1,456
PNEUMONIA 615
MULTIPLE ORGAN DYSFUNCTION SYNDROME 587
RESPIRATORY FAILURE 586
SEPTIC SHOCK 506
BRONCHOPULMONARY ASPERGILLOSIS 447
PYREXIA 444
CONDITION AGGRAVATED 436
SEPSIS 410
ASPERGILLUS INFECTION 359
DISEASE PROGRESSION 308
RENAL FAILURE 286
FEBRILE NEUTROPENIA 270
DRUG RESISTANCE 268
ACUTE MYELOID LEUKAEMIA 249
FUNGAL INFECTION 241
NEUTROPENIA 232
DIARRHOEA 229

Reactions in Hospitalization Reports

Top reactions in 11,781 reports where hospitalization was an outcome.

Reaction Reports
DRUG INTERACTION 980
PYREXIA 979
PNEUMONIA 913
BRONCHOPULMONARY ASPERGILLOSIS 655
FEBRILE NEUTROPENIA 607
ASPERGILLUS INFECTION 524
RESPIRATORY FAILURE 516
CONDITION AGGRAVATED 503
DYSPNOEA 471
DIARRHOEA 449
SEPSIS 420
SEPTIC SHOCK 403
NAUSEA 400
NEUTROPENIA 394
ACUTE KIDNEY INJURY 388
MULTIPLE ORGAN DYSFUNCTION SYNDROME 349
ANAEMIA 341
PANCYTOPENIA 324

Compare voriconazole vs acyclovir →

What the FAERS Data Reveals About voriconazole Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 29,380 voluntary reports linked to voriconazole and its brand equivalents (Vfend), spanning 2004 through 2025. Of those, 8,672 (29.5%) listed death as an outcome and 11,781 (40.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 39% were female and 61% male; age distribution skews toward 45-64, with 7,577 reports in that bracket. The single most reported reaction is drug interaction with 2,315 submissions, followed by death and pyrexia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.